Sign In
Buy ALGS
$4.23
-0.0900 (-2.08%)
At Close: Jul 31, 2026
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 3.6% – Here’s What Happened
02:52am, Friday, 24'th Oct 2025
Shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS - Get Free Report) were down 3.6% on Thursday. The company traded as low as $9.25 and last traded at $9.49. Approximately 76,223 shares traded hands d
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Friday, 17'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
12:30pm, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
08:30am, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
08:30am, Tuesday, 14'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
08:30am, Tuesday, 07'th Oct 2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 Oral presentation will include the full 96-week and post-treatment fo
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
06:06pm, Monday, 08'th Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionabl
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
04:05pm, Wednesday, 03'rd Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
04:05pm, Tuesday, 02'nd Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
10:56am, Tuesday, 19'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionabl
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Friday, 15'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
08:30am, Wednesday, 13'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
07:01pm, Wednesday, 06'th Aug 2025
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $2.35. This compares to earnings of $0.75 per share a year ago.
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
04:05pm, Wednesday, 06'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes thro
